| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.13.5.702 |
| P698 | PubMed publication ID | 8485122 |
| P2093 | author name string | E Murray | |
| J Shepherd | |||
| B A Griffin | |||
| A Gaw | |||
| C J Packard | |||
| M J Caslake | |||
| B D Vallance | |||
| P433 | issue | 5 | |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 702-711 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia | |
| P478 | volume | 13 |
| Q34188082 | Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study |
| Q36455892 | Apolipoproteins AI and B as therapeutic targets |
| Q51565510 | Association between low-density lipoprotein composition and its metabolism in non-insulin-dependent diabetes mellitus. |
| Q31886650 | Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control |
| Q36268257 | Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials |
| Q82274977 | Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study |
| Q42540843 | Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia |
| Q34743413 | Evaluation and management of dyslipidemia in patients with HIV infection |
| Q77052068 | Evidence based approach for the management of mixed hyperlipidaemia |
| Q37786412 | Familial hypercholesterolemia and triglyceride metabolism |
| Q42283686 | Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia |
| Q95794110 | Fenofibrate: a review of its use in dyslipidaemia |
| Q36702091 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus |
| Q24186376 | Fibrates for secondary prevention of cardiovascular disease and stroke |
| Q24204000 | Fibrates for secondary prevention of cardiovascular disease and stroke |
| Q51554081 | Homeostasis model assessment in a population with mixed ethnicity: the 1992 Singapore National Health Survey. |
| Q33693960 | LDL particle size: an important drug target? |
| Q35754362 | Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies |
| Q40964792 | Low-density lipoprotein heterogeneity |
| Q35692886 | Management of dyslipidemias in the age of statins |
| Q41618932 | Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia |
| Q34820339 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia |
| Q34107307 | Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk |
| Q43814334 | Regulation of lipid metabolism and gene expression by fenofibrate in hamsters |
| Q35904825 | Role of fibric acid derivatives in the management of risk factors for coronary heart disease |
| Q34336868 | Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit |
| Q36137264 | The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. |
| Q91994844 | The Polymorphisms of the Peroxisome-Proliferator Activated Receptors' Alfa Gene Modify the Aerobic Training Induced Changes of Cholesterol and Glucose |
| Q38459227 | The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients |
| Q78617409 | The rationale for combination therapy |
| Q33724526 | The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents |
| Q35692031 | The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy |
| Q34027549 | The role of fibric acid derivatives in the secondary prevention of coronary heart disease |
Search more.